Table 4.
Analysis of variance models of plasma ZAAD-1006a pharmacokinetic parameters
| Pharmacokinetic parameter | Statistic | Esomeprazole study | Itraconazole study | Rifampin study | Probenecid study | ||||
|---|---|---|---|---|---|---|---|---|---|
| Pexidartinib alone | Pexidartinib + esomeprazole | Pexidartinib alone | Pexidartinib + itraconazole | Pexidartinib alone | Pexidartinib + rifampin | Pexidartinib alone | Pexidartinib + probenecid | ||
| Cmax, ng/mL | n | 16 | 16 | 13 | 13 | 16 | 16 | 15 | 16 |
| Geometric LS mean | 5289 | 2472 | 3892 | 5858 | 4384 | 5942 | 4162 | 4138 | |
| Geometric LS mean ratio (%) (90% CI) | 46.75 (39.9–54.8) | 150.5 (129.3–173.2) | 135.5 (108.5–169.4) | 99.4 (87.2–113.4) | |||||
| AUC∞, ng•h/mL | n | 16 | 16 | 13 | 13 | 16 | 16 | 15 | 16 |
| Geometric LS mean | 130,366 | 67,646 | 121,049 | 238,561 | 122,014 | 67,655 | 90,364 | 203,649 | |
| Geometric LS mean ratio (%) (90% CI) | 51.9 (46.5–57.9) | 197.1 (179.4–216.5) | 55.5 (46.2–66.5) | 225.4 (200.0–254.0) | |||||
AUC∞ area under the plasma concentration–time curve from 0 to infinity, CI confidence interval, Cmax maximum plasma concentration, LS least square, SD standard deviation